What Do Tesla Delivery Numbers Mean for Tesla Stock?
Tesla (NASDAQ:TSLA) released Q1 delivery numbers, showing a substantial slowdown…
Sell
12
PHBBF Quote, Financials, Valuation and Earnings
Last price:
$1.93
Seasonality move
:
-14.22%
Day range:
$1.93 - $1.93
52-week range:
$1.93 - $2.25
Dividend yield:
1.46%
P/E ratio:
--
P/S ratio:
1.44x
P/B ratio:
1.56x
Volume:
--
Avg. volume:
--
1-year change:
-14.22%
Market cap:
$2.5B
Revenue:
--
EPS (TTM):
--
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
PHBBF
Pharmaron Beijing
|
-- | -- | -- | -- | -- |
|
CORBF
Global Cord Blood
|
-- | -- | -- | -- | -- |
|
HCM
HUTCHMED (China)
|
-- | -- | -- | -- | $26.43 |
|
HKPD
Hong Kong Pharma Digital Technology Holdings
|
-- | -- | -- | -- | -- |
|
PRE
Prenetics Global
|
$12M | -- | 74.63% | -- | $13.00 |
|
RGC
Regencell Bioscience Holdings
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
PHBBF
Pharmaron Beijing
|
$1.93 | -- | $2.5B | -- | $0.03 | 1.46% | 1.44x |
|
CORBF
Global Cord Blood
|
$0.65 | -- | $87M | -- | $0.00 | 0% | 0.41x |
|
HCM
HUTCHMED (China)
|
$13.72 | $26.43 | $2.3B | 68.60x | $0.00 | 0% | 3.80x |
|
HKPD
Hong Kong Pharma Digital Technology Holdings
|
$1.10 | -- | $12.1M | 6.33x | $0.00 | 0% | 0.58x |
|
PRE
Prenetics Global
|
$3.60 | $13.00 | $44M | -- | $0.00 | 0% | 1.73x |
|
RGC
Regencell Bioscience Holdings
|
$36.28 | -- | $472.1M | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
PHBBF
Pharmaron Beijing
|
-- | -0.395 | -- | -- |
|
CORBF
Global Cord Blood
|
-- | -0.478 | -- | -- |
|
HCM
HUTCHMED (China)
|
9.83% | -0.260 | 3.34% | 2.67x |
|
HKPD
Hong Kong Pharma Digital Technology Holdings
|
-- | 0.000 | -- | -- |
|
PRE
Prenetics Global
|
-- | -0.748 | -- | 1.11x |
|
RGC
Regencell Bioscience Holdings
|
-- | -28.439 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
PHBBF
Pharmaron Beijing
|
-- | -- | -- | -- | -- | -- |
|
CORBF
Global Cord Blood
|
-- | -- | -- | -- | -- | -- |
|
HCM
HUTCHMED (China)
|
-- | -- | 4.51% | 4.99% | -- | -- |
|
HKPD
Hong Kong Pharma Digital Technology Holdings
|
-- | -- | -- | -- | -- | -- |
|
PRE
Prenetics Global
|
$3.9M | -$11.8M | -23.16% | -23.16% | -154.7% | -- |
|
RGC
Regencell Bioscience Holdings
|
-- | -- | -- | -- | -- | -- |
Pharmaron Beijing vs. Competitors
-
Which has Higher Returns PHBBF or CORBF?
Global Cord Blood has a net margin of -- compared to Pharmaron Beijing's net margin of --. Pharmaron Beijing's return on equity of -- beat Global Cord Blood's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital PHBBFPharmaron Beijing-- -- -- CORBFGlobal Cord Blood-- -- -- -
What do Analysts Say About PHBBF or CORBF?
Pharmaron Beijing has a consensus price target of --, signalling downside risk potential of --. On the other hand Global Cord Blood has an analysts' consensus of -- which suggests that it could fall by --. Given that Pharmaron Beijing has higher upside potential than Global Cord Blood, analysts believe Pharmaron Beijing is more attractive than Global Cord Blood.
Company Buy Ratings Hold Ratings Sell Ratings PHBBFPharmaron Beijing0 0 0 CORBFGlobal Cord Blood0 0 0 -
Is PHBBF or CORBF More Risky?
Pharmaron Beijing has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Global Cord Blood has a beta of -0.640, suggesting its less volatile than the S&P 500 by 163.968%.
-
Which is a Better Dividend Stock PHBBF or CORBF?
Pharmaron Beijing has a quarterly dividend of $0.03 per share corresponding to a yield of 1.46%. Global Cord Blood offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pharmaron Beijing pays -- of its earnings as a dividend. Global Cord Blood pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PHBBF or CORBF?
Pharmaron Beijing quarterly revenues are --, which are smaller than Global Cord Blood quarterly revenues of --. Pharmaron Beijing's net income of -- is lower than Global Cord Blood's net income of --. Notably, Pharmaron Beijing's price-to-earnings ratio is -- while Global Cord Blood's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pharmaron Beijing is 1.44x versus 0.41x for Global Cord Blood. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PHBBFPharmaron Beijing1.44x -- -- -- CORBFGlobal Cord Blood0.41x -- -- --
-
Which has Higher Returns PHBBF or HCM?
HUTCHMED (China) has a net margin of -- compared to Pharmaron Beijing's net margin of --. Pharmaron Beijing's return on equity of -- beat HUTCHMED (China)'s return on equity of 4.99%.
Company Gross Margin Earnings Per Share Invested Capital PHBBFPharmaron Beijing-- -- -- HCMHUTCHMED (China)-- -- $854.7M -
What do Analysts Say About PHBBF or HCM?
Pharmaron Beijing has a consensus price target of --, signalling downside risk potential of --. On the other hand HUTCHMED (China) has an analysts' consensus of $26.43 which suggests that it could grow by 92.64%. Given that HUTCHMED (China) has higher upside potential than Pharmaron Beijing, analysts believe HUTCHMED (China) is more attractive than Pharmaron Beijing.
Company Buy Ratings Hold Ratings Sell Ratings PHBBFPharmaron Beijing0 0 0 HCMHUTCHMED (China)10 2 0 -
Is PHBBF or HCM More Risky?
Pharmaron Beijing has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison HUTCHMED (China) has a beta of 0.658, suggesting its less volatile than the S&P 500 by 34.171%.
-
Which is a Better Dividend Stock PHBBF or HCM?
Pharmaron Beijing has a quarterly dividend of $0.03 per share corresponding to a yield of 1.46%. HUTCHMED (China) offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pharmaron Beijing pays -- of its earnings as a dividend. HUTCHMED (China) pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PHBBF or HCM?
Pharmaron Beijing quarterly revenues are --, which are smaller than HUTCHMED (China) quarterly revenues of --. Pharmaron Beijing's net income of -- is lower than HUTCHMED (China)'s net income of --. Notably, Pharmaron Beijing's price-to-earnings ratio is -- while HUTCHMED (China)'s PE ratio is 68.60x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pharmaron Beijing is 1.44x versus 3.80x for HUTCHMED (China). Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PHBBFPharmaron Beijing1.44x -- -- -- HCMHUTCHMED (China)3.80x 68.60x -- --
-
Which has Higher Returns PHBBF or HKPD?
Hong Kong Pharma Digital Technology Holdings has a net margin of -- compared to Pharmaron Beijing's net margin of --. Pharmaron Beijing's return on equity of -- beat Hong Kong Pharma Digital Technology Holdings's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital PHBBFPharmaron Beijing-- -- -- HKPDHong Kong Pharma Digital Technology Holdings-- -- -- -
What do Analysts Say About PHBBF or HKPD?
Pharmaron Beijing has a consensus price target of --, signalling downside risk potential of --. On the other hand Hong Kong Pharma Digital Technology Holdings has an analysts' consensus of -- which suggests that it could fall by --. Given that Pharmaron Beijing has higher upside potential than Hong Kong Pharma Digital Technology Holdings, analysts believe Pharmaron Beijing is more attractive than Hong Kong Pharma Digital Technology Holdings.
Company Buy Ratings Hold Ratings Sell Ratings PHBBFPharmaron Beijing0 0 0 HKPDHong Kong Pharma Digital Technology Holdings0 0 0 -
Is PHBBF or HKPD More Risky?
Pharmaron Beijing has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Hong Kong Pharma Digital Technology Holdings has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock PHBBF or HKPD?
Pharmaron Beijing has a quarterly dividend of $0.03 per share corresponding to a yield of 1.46%. Hong Kong Pharma Digital Technology Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pharmaron Beijing pays -- of its earnings as a dividend. Hong Kong Pharma Digital Technology Holdings pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PHBBF or HKPD?
Pharmaron Beijing quarterly revenues are --, which are smaller than Hong Kong Pharma Digital Technology Holdings quarterly revenues of --. Pharmaron Beijing's net income of -- is lower than Hong Kong Pharma Digital Technology Holdings's net income of --. Notably, Pharmaron Beijing's price-to-earnings ratio is -- while Hong Kong Pharma Digital Technology Holdings's PE ratio is 6.33x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pharmaron Beijing is 1.44x versus 0.58x for Hong Kong Pharma Digital Technology Holdings. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PHBBFPharmaron Beijing1.44x -- -- -- HKPDHong Kong Pharma Digital Technology Holdings0.58x 6.33x -- --
-
Which has Higher Returns PHBBF or PRE?
Prenetics Global has a net margin of -- compared to Pharmaron Beijing's net margin of -137.21%. Pharmaron Beijing's return on equity of -- beat Prenetics Global's return on equity of -23.16%.
Company Gross Margin Earnings Per Share Invested Capital PHBBFPharmaron Beijing-- -- -- PREPrenetics Global50.75% -$0.84 $180.1M -
What do Analysts Say About PHBBF or PRE?
Pharmaron Beijing has a consensus price target of --, signalling downside risk potential of --. On the other hand Prenetics Global has an analysts' consensus of $13.00 which suggests that it could grow by 261.11%. Given that Prenetics Global has higher upside potential than Pharmaron Beijing, analysts believe Prenetics Global is more attractive than Pharmaron Beijing.
Company Buy Ratings Hold Ratings Sell Ratings PHBBFPharmaron Beijing0 0 0 PREPrenetics Global1 0 0 -
Is PHBBF or PRE More Risky?
Pharmaron Beijing has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Prenetics Global has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock PHBBF or PRE?
Pharmaron Beijing has a quarterly dividend of $0.03 per share corresponding to a yield of 1.46%. Prenetics Global offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pharmaron Beijing pays -- of its earnings as a dividend. Prenetics Global pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PHBBF or PRE?
Pharmaron Beijing quarterly revenues are --, which are smaller than Prenetics Global quarterly revenues of $7.8M. Pharmaron Beijing's net income of -- is lower than Prenetics Global's net income of -$10.7M. Notably, Pharmaron Beijing's price-to-earnings ratio is -- while Prenetics Global's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pharmaron Beijing is 1.44x versus 1.73x for Prenetics Global. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PHBBFPharmaron Beijing1.44x -- -- -- PREPrenetics Global1.73x -- $7.8M -$10.7M
-
Which has Higher Returns PHBBF or RGC?
Regencell Bioscience Holdings has a net margin of -- compared to Pharmaron Beijing's net margin of --. Pharmaron Beijing's return on equity of -- beat Regencell Bioscience Holdings's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital PHBBFPharmaron Beijing-- -- -- RGCRegencell Bioscience Holdings-- -- -- -
What do Analysts Say About PHBBF or RGC?
Pharmaron Beijing has a consensus price target of --, signalling downside risk potential of --. On the other hand Regencell Bioscience Holdings has an analysts' consensus of -- which suggests that it could fall by --. Given that Pharmaron Beijing has higher upside potential than Regencell Bioscience Holdings, analysts believe Pharmaron Beijing is more attractive than Regencell Bioscience Holdings.
Company Buy Ratings Hold Ratings Sell Ratings PHBBFPharmaron Beijing0 0 0 RGCRegencell Bioscience Holdings0 0 0 -
Is PHBBF or RGC More Risky?
Pharmaron Beijing has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Regencell Bioscience Holdings has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock PHBBF or RGC?
Pharmaron Beijing has a quarterly dividend of $0.03 per share corresponding to a yield of 1.46%. Regencell Bioscience Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pharmaron Beijing pays -- of its earnings as a dividend. Regencell Bioscience Holdings pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PHBBF or RGC?
Pharmaron Beijing quarterly revenues are --, which are smaller than Regencell Bioscience Holdings quarterly revenues of --. Pharmaron Beijing's net income of -- is lower than Regencell Bioscience Holdings's net income of --. Notably, Pharmaron Beijing's price-to-earnings ratio is -- while Regencell Bioscience Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pharmaron Beijing is 1.44x versus -- for Regencell Bioscience Holdings. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PHBBFPharmaron Beijing1.44x -- -- -- RGCRegencell Bioscience Holdings-- -- -- --
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Chewy a Growth Stock to Buy?
It might be a surprise to learn that during the…
Is Realty Income the Best Dividend Stock to Buy Long-Term?
Realty Income (NYSE:O) is a longstanding real estate investment trust…
Stock Ideas
Sell
45
Is AAPL Stock a Buy?
Market Cap: $3T
P/E Ratio: 33x
Buy
53
Is MSFT Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 33x
Sell
50
Is NVDA Stock a Buy?
Market Cap: $2.7T
P/E Ratio: 38x
Alerts
Buy
52
RGC alert for Apr 12
Regencell Bioscience Holdings [RGC] is up 29.14% over the past day.
Buy
52
SLP alert for Apr 12
Simulations Plus [SLP] is up 26.73% over the past day.
Buy
89
GDXU alert for Apr 12
MicroSectors Gold Miners 3X Leveraged ETN [GDXU] is up 15.9% over the past day.
